Press Releases by "Ono Pharmaceutical Co., Ltd."

• ONO Receives Approval for OPDIVO® (Nivolumab) Intravenous Infusion for Treatment of Recurrent or Metastatic Head and Neck Cancer as a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan (63.8KB)
  [ Pharmaceuticals | 2017-03-24]
• Ono Enters into Collaboration Agreement with X-Chem, Inc. (53.8KB)
  [ Pharmaceuticals | 2017-03-21]
• Announcement on posting of Corporate Report 2016
  [ Pharmaceuticals | 2016-09-05]
• Notice of Resolutions Passed at The 68th Ordinary General Shareholders' Meeting
  [ Pharmaceuticals | 2016-06-29]
• Notice to Convene the 68th Ordinary General Shareholders' Meeting
  [ Pharmaceuticals | 2016-06-01]
• Notice to Convene the 67th Ordinary General Shareholders' Meeting
  [ Pharmaceuticals | 2015-06-01]
• (Warning) Be cautious about SNS sites under the name of ‘ONO PHARMACEUTICAL CO., LTD.’
  [ Pharmaceuticals | 2015-04-20]
• Notice to Resolutions Passed at the 66th Ordinary General Shareholders' Meeting
  [ Pharmaceuticals | 2014-06-27]
• Notice to Convene the 66th Ordinary General Shareholders' Meeting
  [ Pharmaceuticals | 2014-06-05]
• Approval Received for Rivastach® Patch, for the treatment of Alzheimer's disease
  [ Pharmaceuticals | 2011-04-22]
• Launch of Orally Disintegrating Tablet of Staybla Tablets 0.1mg, a Drug for Overactive Bladder
  [ Pharmaceuticals | 2011-04-05]
• Ono Enters into License Agreement with OncoTherapy for New Therapeutic Cancer Peptide Vaccines
  [ Pharmaceuticals | 2011-03-29]
• Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease
  [ Pharmaceuticals | 2011-01-11]
• Results of Phase Ⅱb Study of Carfizomib were Presented at the 52nd American Society of Hematology Annual Meeting
  [ Pharmaceuticals | 2010-12-10]
• Approval Received for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
  [ Pharmaceuticals | 2010-11-11]
• Announcement on Acquisition of the Company's Own Shares
  [ Pharmaceuticals | 2010-11-04]
• Ono and MSD Submit Additional Indication Application for Sitagliptin Combination Therapy with Insulin
  [ Pharmaceuticals | 2010-10-28]
• Application Filed in Japan for an Intravenous Antiemetic Selective Neurokinin-1 (NK1) Receptor Antagonist
  [ Pharmaceuticals | 2010-09-24]
• Application for RECALBON® Tablets 50mg/ Bonoteo® Tablets 50mg,A Monthly Oral Osteoporosis Treatment in Japan
  [ Pharmaceuticals | 2010-09-10]
• Ono Announces Carfilzomib Development and Commercialization Agreement with Onyx Pharmaceuticals for Japan
  [ Pharmaceuticals | 2010-09-08]

Most Popular: "Ono Pharmaceutical Co., Ltd."